We found for
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies

Early Experience with Health Technology Assessment of Gene Therapies in the United States: Pricing and Paying for Cures

Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research
